Sonidegib

Product Description

Sonidegib is a potent Smoothened (Smo) receptor antagonist (IC₅₀ values are 1.3 nM and 2.5 nM at mouse and human receptors, respectively). Inhibits growth of a variety of tumor types including basal cell carcinoma, small cell lung cancer and medulloblastoma. Sonidegib inhibits Hh pathway in CD34⁺ chronic myeloid leukemia cells; it reduces both the number of cells and self-renewal ability. Brain penetrant and orally bioavailable.

Solubility

Preparing Stock Solutions for Sonidegib

The following data is based on the product molecular weight 485.51

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.06 mL	10.30 mL	20.60 mL
5 mM	0.41 mL	2.06 mL	4.12 mL
10 mM	0.21 mL	1.03 mL	2.06 mL
50 mM	0.04 mL	0.21 mL	0.41 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Irvine Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. Sci.Rep. 2016 PMID: 27157927
• Pan Discovery of NVP-LDE225, a potent and selective smoothened antagonist. ACS Med.Chem.Lett. 2010 PMID: 24900187